FLUDARABINE ACCORD 25MG/ML INJ/INF CNC SOL 1X2ML

What is the maximum co-payment for FLUDARABINE ACCORD?

If the insurance company contributes, the maximum co-payment is 419,87 Kč. The maximum pharmacy price is 2 017,47 Kč. A pharmacy may provide the medicine for a lower price, but not for a higher price.

Does the medicine have reimbursement from public health insurance?

Yes, but only during an outpatient procedure. When dispensed on prescription, the patient always pays the full price.

Does FLUDARABINE ACCORD have a counted co-payment set?

No, this medicine has no counted co-payment.

How much does the insurance company pay for one dispensed reimbursed pack?

1 597,60 Kč.

Does the insurance company pay a higher amount in some cases?

No, the medicine has no increased reimbursement.

Does the medicine have an indication restriction?

Fludarabin je hrazen při léčbě chronické lymfocytární leukemie (CLL) B-buněčného typu u pacientů, kteří mají dostatečnou rezervu kostní dřeně. Léčba přípravkem v první linii by měla být zahájena pouze u pacientů v pokročilém stádiu choroby, tj. Rai III/IV (Binet C) nebo Rai I/II (Binet A/B), kteří mají doprovodné symptomy nebo známky progredujícího onemocnění.

Is it available without a medical prescription?

No, the medicine cannot be obtained without a prescription.

Which medical specialist may prescribe FLUDARABINE ACCORD?

clinical oncology, pediatric oncology and hematology, radiation oncology and oncogynecology
hematology and transfusion medicine, pediatric oncology and hematology

What is the composition of FLUDARABINE ACCORD?

Fludarabin-fosfát (25 mg), mannitol, dihydrát hydrogenfosforečnanu sodného, voda pro injekci (1 ml). More information about the composition can be found in the SPC, section 6.1.

Where can I find information about correct use of the medicine?

Which medicines are similar to FLUDARABINE ACCORD?

The medicine belongs to ATC group L01BB05 – FLUDARABIN. Medicines with the same active substance can be found here.

Who manufactures FLUDARABINE ACCORD?

ACCORD HEALTHCARE POLSKA Sp. z o.o., Varšava (PL)

Is the medicine in shortage?

The latest report from the manufacturer is from 14. 2. 2025. Production was terminated with effect from 1. 4. 2025. The manufacturer lists medicines with the following code as a potential substitute: